Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients According to the Standard for "Re-examination of New Drugs"

Trial Profile

Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients According to the Standard for "Re-examination of New Drugs"

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 May 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Intermediate uveitis; Panuveitis; Posterior uveitis
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 09 May 2018 Planned number of patients changed from 600 to 305.
    • 19 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 15 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top